Necrostatin-1

For research use only. Not for use in humans.

製品コードS8037

Necrostatin-1化学構造

分子量(MW):259.33

Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.

サイズ 価格(税別) 在庫  
JPY 18100 あり
JPY 46800 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(52)

製品安全説明書

TNF-alpha阻害剤の選択性比較

生物活性

製品説明 Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.
特性 A powerful tool for characterizing the role of necroptosis with characterized primary target.
ターゲット
RIP1 [1]
(293T cells)
490 nM(EC50)
体外試験

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. [1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NYnhVotuS2WubDDWbYFjcWyrdImgRZN{[Xl? NED4SXE2OMLizszN NFPyXXczPMLiaB?= Moi1bY5pcWKrdIOgUW1UNWmwZIXj[YQh[2WubDDk[YF1cA>? NIfx[JgzPjR5MkeyNy=>
MEFs  M{XqV2NmdGxiVnnhZoltcXS7IFHzd4F6 MXuxNQKBkc7:TR?= MoTROFghcA>? MlfmSG1UVw>? M2LPPYlvcGmkaYTzJJpXSURvcILvcY91\WRiZHXheIghd2ZiQ17PWFMu\GWybHX0[YQhVUWIcx?= Mn;rNlY1Ozd5OEm=
BMDM  Mo\RSpVv[3Srb36gRZN{[Xl? M3nKfVExyqEQvF2= MVmzNOKhdWmw NIjDbYFxem:2ZXP0d{Bk\WyuczDmdo9uKFSDS1mtbY5lfWOnZDDMSGghemWuZXHz[S=> M4fYdlI3OzhzNkCx
NCI-H28 MmLjR4VtdCCYaXHibYxqfHliQYPzZZk> M2m3bVExyqEQvF2= MoDpNlTDqGh? NGTSPZZxemW4ZX70d{BFSVCHLXnu[JVk\WRicnXkeYN1cW:wIH;mJG5EUS2KMkigZ4VtdCC4aXHibYxqfHoEoB?= MVGyOlAxPDF|OB?=
MiaPaCa-2 MX7GeY5kfGmxbjDBd5NigQ>? NFHtelMzOCEQvF2= MkfLNlQhcA>? MV;k[YNz\WG|ZYOgeIhmKGWjcnz5JI5m[3KxdHnjJINmdGy| M2rDe|I3ODByNkC3
BxPC-3 MYHGeY5kfGmxbjDBd5NigQ>? NVLkd3kxOjBizszN NI\CcVYzPCCq M1vV[IRm[3KnYYPld{B1cGViZXHycJkhdmWlcn;0bYMh[2WubIO= NI\YfIkzPjByME[wOy=>
SGC-7901 NUfs[VY6S2WubDDWbYFjcWyrdImgRZN{[Xl? NE\tSWQ{OMLizszN M1PNblHDqGh? MWrzeZBxemW|c3XzJI95[WyrcHzheIlvNW2nZHnheIVlKGOnbHyg[IVifGh? NXvZfoRlOjV5NkewO|Y>
KMS-12-PE  MkPBR4VtdCCYaXHibYxqfHliQYPzZZk> M3nsV|YxKM7:TR?= NV7UOnY3PSCq NUG4SmprcW6qaXLpeJMhW0iNLXnu[JVk\WRiY3XscEBl\WG2aB?= NWLNOJR7OjV3M{CwPVg>
L929-A  MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3vnblUxyqEQvF5CpC=> MYKyOEBp MnHUZoxw[2u|IGTOSu6yNWmwZIXj[YQh[2WubDDk[YF1cA>? MUiyOVM6QDV2MB?=
L929-N  MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NInyco02OMLizszNxsA> NFf5VpczPCCq NGG2W3ZjdG:la4OgWG5H|rFvaX7keYNm\CClZXzsJIRm[XSq M1z6[FI2Ozl6NUSw
L929-A  MXXGeY5kfGmxbjDBd5NigQ>? MWK1NOKh|ryPwrC= M2fjc|EzKGh? NYXYfWl[[myxY3vzJJRp\SClbHXheoFo\SCxZjDDZZNx[XOnLUOgZY5lKFCDUmC= M3m2UVI2Ozl6NUSw
L929-N  M3\NZmZ2dmO2aX;uJGF{e2G7 NYL2VFV1PTEEoN88UeKh MoXINVIhcA>? MWLicI9kc3NidHjlJINt\WG4YXflJI9nKEOjc4Dhd4UuOyCjbnSgVGFTWA>? NIOwbm4zPTN7OEW0NC=>
L929 MYrGeY5kfGmxbjDBd5NigQ>? MnnQOVDDqM7:TdMg MWWxNkBp NEDlT|NqdmirYnn0d{BVVkcQsT3pcoR2[2WmIFLp[EBkdGWjdnHn[S=> NYiwSI9bOjV|OUi1OFA>
L929-A MonHSpVv[3Srb36gRZN{[Xl? M1PEb|UxyqEQvF5CpC=> NW\VVmltOTJiaB?= Mk\SbY5pcWKrdIOgeIhmKFSQRt8xMYlv\HWlZXSgcI9{eyCxZjDtbZRw[2ixbnTybYFtKG2nbXLyZY5mKHCncn3lZYJqdGm2eR?= NWG5TnNkOjV|OUi1OFA>
L929 NXLwWGVzS2WubDDWbYFjcWyrdImgRZN{[Xl? MYCzNOKh|ryP NH3DXmgyyqCq MnHGbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRibH;zd{Bw\iClZXzsJJZq[WKrbHn0fS=> MlLpNlUxQTV5NEK=
L929 M{jDVmNmdGxiVnnhZoltcXS7IFHzd4F6 MXyzNOKh|ryP NHzx[m8yyqCq MnrWbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiY3zlZZZi\2Vib3[gWI9xdyCL NYCy[pBTOjVyOUW3OFI>
Huh7 M2DPb2NmdGxiVnnhZoltcXS7IFHzd4F6 M1K4TFUxKML3TR?= MlqyNlQwPDhiaB?= NX\vToM4TE2VTx?= M3fVOJBz\X[nboTzJINmdGxiZHXheIghd2ZiclHkTGNXKGOxLXnu[oVkfGWmIFj1bFch[2WubIO= NHPBc4UzPDl5M{K0NC=>
OHC NH6zZ41HfW6ldHnvckBCe3OjeR?= NUGzenJ[OzBy4pEJ{txO M3LLR2ROW09? NUe5Tlk{cW6lcnXhd4V{KG6xaYPlMYlv\HWlZXSgZ49v\GWwc3XkJI52[2ynaR?= MoP2NlQ5PzR5M{S=
OHC MonrSpVv[3Srb36gRZN{[Xl? MkHGN|Ax6oDLzszN NHniZYtFVVOR NVjBXIVs\GWlcnXhd4V{KG6xaYPlMYlv\HWlZXSgd5dwdGynbjDueYNt\WoEoB?= MlzDNlQ5PzR5M{S=
OHC MV;GeY5kfGmxbjDBd5NigQ>? NHX3UpI{ODEkgJpOwG0> NF\ZW4ZFVVOR MmTQdoV{fWy2czDpckBiKHKnZIXjeIlwdiCxZjDuc4l{\S2rbnT1Z4VlKFKLUEGgZY5lKFKLUEOgbY1ufW6xZnz1c5Jme2OnbnPl Ml3oNlQ5PzR5M{S=
OHC MnXoSpVv[3Srb36gRZN{[Xl? NIXJb|I{ODEkgJpOwG0> NGqySmNFVVOR MmH5[IlucW6rc3jld{Bvd2m|ZT3pcoR2[2WmIFHNVGsh[WO2aY\heIlwdg>? MXSyOFg4PDd|NB?=
OHC M3rIOmZ2dmO2aX;uJGF{e2G7 NHu2fFY{ODEkgJpOwG0> NFrQOmFFVVOR MlXkbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiYYDvdJRwfGmlIF;IR5Mhf2m2aH;1eEBidHSncnnu[{B1cGVibHX2[Yx{KG:oIFPDPEBi\nSncjDuc4l{\SCneIDvd5Vz\Q>? Mnf3NlQ5PzR5M{S=
SK-Hep1 NWjBW5ZpTnWwY4Tpc44hSXO|YYm= M{Lae|Yx6oDLzszNxsA> MUKxPQKBkWh? MVPicI9kc3QEoN8yMYxieGGlaH;u[U1qdmS3Y3XkJI1wenCqb3zv[4lk[WxiY3jhcodmNCClZXzsJIRm[XSqIHHu[EBRUSC3cIThb4U> MYOyOFg{OjZyMh?=
SK-Hep1 NG\YSnpHfW6ldHnvckBCe3OjeR?= MUS2NQKBkc7:TdMg NYLS[GluOTkkgJno M{XMWIlvcGmkaYTzJO6zNUyjcHHjbI9v\S2rbnT1Z4VlKGynYXvh[4Uhd2ZiSF3HRk0yyqB? NUTsTZNOOjR6M{K2NFI>
SK-Hep1 MnntSpVv[3Srb36gRZN{[Xl? MYG2NQKBkc7:TdMg MVSxPQKBkWh? MV3icI9kc3QEoN8yMYxieGGlaH;u[U1u\WSrYYTl[EBRSVJiYXPjeY12dGG2aX;uJIFv\CCDSV[geJJidnOub3PheIlwdiC2bzD0bIUh[3m2b4PvcOKh NV\JOItuOjR6M{K2NFI>
L-540  MVXGeY5kfGmxbjDBd5NigQ>? NYHhNHJIPjEkgJpOwI0> NHTLZoYy6oDLaB?= MYPwdoV3\W62czD0bIUh\2WwZYLheIlwdiCxZjDSU3M> MoP4NlQ2PjF3MUm=
L-540  M{myVWZ2dmO2aX;uJGF{e2G7 NV3wZ3ZWPjEkgJpOwI0> NUHCRoYyOeLCiXi= M2XCSpBz\X[nboTzJJRp\SCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJIRmeG:uYYLpfoF1cW:w MoXvNlQ2PjF3MUm=
L-540  M1rDZmNmdGxiVnnhZoltcXS7IFHzd4F6 NF75dJg3OOLCid88cS=> MkPWNgKBkWh? MlK5doVlfWOnczD0bIUhT2m4aX7vd5RifC:Vb4Lh[oVvcWJvaX7keYNm\CClZXzsJIRm[XSq MlfzNlQ2PjF3MUm=
AGS NFrVbYRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{Tab|Yx6oDLzszt MnPWNgKBkWh? NXS4Xm5UeHKndnXueJMhe2ira3;ubY4ucW6mdXPl[EBk\WyuIHTlZZRp MUOyOFQ3OzF7OR?=
NRK-52E  NVS5S2ZpS2WubDDWbYFjcWyrdImgRZN{[Xl? NEDJOnEzOCEQvF2= MVmyOEBp M1zOcJBzd3SnY4TzJINmdGy|IH\yc40h[2WubDDk[YF1cCClYYXz[YQh[nliaYPjbIVucWFiaX7qeZJ6 MVSyOFM2OTh2NR?=
NRK-52E  NH3Edo5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M17PWVIxKM7:TR?= NXnEW29IOjRiaB?= M1zPUolv[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDh[pRmeiCWTl[t{tEhW3SrbYXsZZRqd25iYX7kJGFVWCCGZYDs[ZRqd25? MXyyOFM2OTh2NR?=
NRK-52E  MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3K4elIxKM7:TR?= M1;Db|I1KGh? NHTW[mhqdmirYnn0d{BqdmO{ZXHz[YQhTHKyMTDwdo91\WmwIHX4dJJme3Orb36gZYZ1\XJiVF7GMe6yKFO2aX31cIF1cW:wIHHu[EBCXFBiRHXwcIV1cW:w MlvHNlQ{PTF6NEW=
L929 MnTzSpVv[3Srb36gRZN{[Xl? MlLvNk82yqEQvHevcYzDqA>? M3HuclI1yqCq Mk[wdoV3\XK|ZXSgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IGTOSu6yKGGub37lJIF{KHenbHygZZMhXE6IzsJCpEvDqHqYQVS= NGOwSngzOzl2MUe2PS=>
L929 M1\sOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ftWlIwPcLizsznM41tyqB? M3H6bVI1yqCq MknPdoV3\XK|ZYOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZY5lKGOnbHyg[IVifGhiaX7keYNm\CCkeTDUUmbPuSCjbH;u[UBieyC5ZXzsJIF{KFSQRt8xxsAsyqC8VlHE NXq3fJVlOjN7NEG3Olk>
L929 MmHnSpVv[3Srb36gRZN{[Xl? MmPnNuKh|rypL33sxsA> NYnEcVl1OjUEoHi= NGTMRWdxem:vb4TzJINie3Cjc3WtOkApeDJyKTDhZ5Rqfmm2eTDhcoQheHKxY3HzdIF{\S14IHPs[YF3[Wen NYfoSWQ4OjN7NEG3Olk>
L929 Mny0SpVv[3Srb36gRZN{[Xl? MkDmOeKh|rypL33s M3j0dFI1yqCq NXXk[m5z[myxY3vzJJpXSURiaX7keYNm\CCwZXPyc5B1d3OrczDhcoQh[XW2b4DoZYd6 NIL1ZmYzOzl2MUe2PS=>
C6 M1G0VWNmdGxiVnnhZoltcXS7IFHzd4F6 NGnTWIkyKG2vb3yvUC=> NGLm[Jc{KGh? M1fwWoF1fGWwdXH0[ZMhW2ira3;ubY4hcW6mdXPl[EBodGmxbXGgZ4VtdCCmZXH0bC=> MmLhNlM5PDB2NEG=
U87 NEXjb5hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF;YVFgyKG2vb3yvUC=> NELPW|A{KGh? NVHYWYFz[XS2ZX71ZZRmeyCVaHnrc45qdiCrbnT1Z4VlKGeuaX;tZUBk\WyuIHTlZZRp MWWyN|g1ODR2MR?=
C6 MVnDfZRwfG:6aXPpeJkhSXO|YYm= NX\YW|luOSCvbX;sM2w> NWfRUYg2OyCq Mmr0Zoxw[2u|IIPobYtwdmmwIHnu[JVk\WRibnXjdo9{cXN? NFH4T4EzOzh2MES0NS=>
U87 NXu2UFRGS3m2b4TvfIlkcXS7IFHzd4F6 MlzKNUBudW:uL1y= NFy4WXQ{KGh? M{fvOoJtd2OtczDzbIlsd26rbjDpcoR2[2WmIH7lZ5Jwe2m| MoTFNlM5PDB2NEG=
C6 MX3GeY5kfGmxbjDBd5NigQ>? M2X6UFEhdW2xbD;M MXWxMlUuOyCq NFHmdVR{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKFKLUD2xJINifXOnZDDifUB{cGmtb37pci=> NH;oTZIzOzh2MES0NS=>
U87 M2DKRWZ2dmO2aX;uJGF{e2G7 NEDDUngyKG2vb3yvUC=> NGrUNXkyNjVvMzDo Mnzjd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBTUVBvMTDjZZV{\WRiYomgd4hqc2:waX6= M4fKfFI{QDRyNESx
TE671 NH3KOYVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NY\lO4d7PDEkgJpOwIcwdW{EoB?= MYiyOEBp M1HrPZJme2O3ZYOgS3gyPS1yN{CtbY5lfWOnZDDsc5N{KG:oIHPlcIwhfmmjYnnsbZR6 MXeyN|c1PDJ7Nh?=
RMS13 M4PxbWNmdGxiVnnhZoltcXS7IFHzd4F6 M2D3OVQx6oDLzsznM41tyqB? MYmyOEBp MVXy[ZNkfWW|IFfYNVUuODdyLXnu[JVk\WRibH;zd{Bw\iClZXzsJJZq[WKrbHn0fS=> MXuyN|c1PDJ7Nh?=
MEFs MnXQR5l1d3SxeHnjbZR6KEG|c3H5 MUKyM|YwOjBizszN NF\EUmYyQCCq MXTpcohq[mm2czDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGhiaX6gVoVtSSCNTzDNSWZ{ MmDQNlM4Ojd3OEG=
MEFs NYq1fJVyTnWwY4Tpc44hSXO|YYm= NGLDPJozOMLizszN NIm1SZYyNzJxNDDo MmXxd5VxeHKnc4Pld{BVVkcQsT3pcoR2[2WmIGLJVGsyKHCqb4PwbI9zgWyjdHnvci=> NVP2[5JKOjN5Mke1PFE>
ΔN-Karpas 299  NFmyOFdEgXSxdH;4bYNqfHliQYPzZZk> NULMRYI6OjEEoN88US=> M2LvT|E3KGh? Mnj1bY5pcWKrdIOgR2Q{OC2rbnT1Z4VlKGOnbHyg[IVifGh? NHi1ZpUzOzV2NUmzPC=>
MM.1S  MWnDfZRwfG:6aXPpeJkhSXO|YYm= M3vJXVkxKML3TR?= MV[xJIg> Mn\hZoxw[2u|IFLBXUAyOS15MEiyJIlv\HWlZXSgdoFxcWRiY3XscEB{f2WubHnu[y=> Mk[0NlM2OjdzNUS=
KMS-12-BM NHHW[JVEgXSxdH;4bYNqfHliQYPzZZk> M4S0SlkxKML3TR?= NGLkTpoyKGh? MWTicI9kc3NiQlHZJFEyNTdyOEKgbY5lfWOnZDDyZZBq\CClZXzsJJN4\WyuaX7n MUOyN|UzPzF3NB?=
HT-22  NHPSfXZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MU[xNOKh|ryP NELJVYEyOsLiaB?= Ml;oSG1UVw>? NHG1SYlxem:2ZXP0d{Bi\2GrboP0JIdtfXSjbXH0[U1qdmS3Y3XkJINmdGxiZHXheIg> NIrBbYUzOzNyN{e1Ni=>
HT-22  MkfZSpVv[3Srb36gRZN{[Xl? MVWyOeKh|ryP NXzES|VbOOLCk{OwxsBucW5? MXjEUXNQ MUjpcohq[mm2czDFVmshSWO2aY\heIlwdiCrbnT1Z4VlKGK7IHfseZRidWG2ZR?= NWraSI1GOjN|MEe3OVI>
NIH3T3  NYnYUWt2TnWwY4Tpc44hSXO|YYm= NIXuc2gyOC93MDFOwG0> NFLGW|YyNzNiaB?= MY\hcYVtcW:{YYTld{BVVkcQsT3kdol3\W5iY3;tdIxmgCCob4LtZZRqd25? NEjFcWIzOzJ4MU[3Oy=>
SH-EP NFfNTHhCeG:ydH;zbZMhSXO|YYm= NH33SWYyOOLCid88UeKh NF;U[HU4OuLCiXlCpC=> NUTqfoFVcW6qaXLpeJMhUUGSIHnubIljcXSxcj2gZY5lKEyneHH0eY12dWGkLXnu[JVk\WRiYYDvdJRwe2m| M1LOelIzQDlyM{Ky
HL60 MUjBdI9xfG:|aYOgRZN{[Xl? NYG0PY9jPjBizszN MlnnNVIhcA>? NGrzXlBmdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NH7QWZkzOjh|N{[4PS=>
HL60/Adr NGn0R4RCeG:ydH;zbZMhSXO|YYm= NED5XYE3OCEQvF2= MX2xNkBp MVrlcohidmOnczDzbIlsd26rbj3pcoR2[2WmIHHwc5B1d3Orcx?= M3LxVlIzQDN5Nki5
K562 NG\XSGpCeG:ydH;zbZMhSXO|YYm= NFfaRpE3OCEQvF2= NEnzOWEyOiCq NWnWSoo{\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM> NFHpTnUzOjh|N{[4PS=>
K562/Adr  MVXBdI9xfG:|aYOgRZN{[Xl? NEfvd4E3OCEQvF2= MXexNkBp MXPlcohidmOnczDzbIlsd26rbj3pcoR2[2WmIHHwc5B1d3Orcx?= M{G2TVIzQDN5Nki5
HL60 NV7EWYh3TnWwY4Tpc44hSXO|YYm= M1nMU|YxKM7:TR?= NYfyWZdQOTJiaB?= NGrDUGxifWevZX70d{B1cGViY3HzdIF{\S1|IHHjeIl3cXS7 MVGyNlg{PzZ6OR?=
HL60/Adr NIDIdm5HfW6ldHnvckBCe3OjeR?= NXnR[|hyPjBizszN NUfV[4FbOTJiaB?= MkjvZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>? MnnsNlI5Ozd4OEm=
K562 NIq2UHlHfW6ldHnvckBCe3OjeR?= M4rLZlYxKM7:TR?= MkXuNVIhcA>? MlX3ZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>? NYHjdnRyOjJ6M{e2PFk>
K562/Adr  MWLGeY5kfGmxbjDBd5NigQ>? NEXzNFY3OCEQvF2= NUnxUmI6OTJiaB?= M3nw[oF2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl? MojMNlI5Ozd4OEm=
HL60 MYrGeY5kfGmxbjDBd5NigQ>? MY[2NEDPxE1? NF;C[FgyOiCq NW\OVHVMcW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G|cHHz[UA5KGGwZDC5 NF3RbmgzOjh|N{[4PS=>
HL60/Adr NUjzVohXTnWwY4Tpc44hSXO|YYm= MkS4OlAh|ryP NF7kZXQyOiCq M3XjPYlv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG|ZYOsJINie3Cjc3WgPEBidmRiOR?= NVv1bHRsOjJ6M{e2PFk>
K562 NWnlbVBNTnWwY4Tpc44hSXO|YYm= M2LRSVYxKM7:TR?= NFnDSoMyOiCq MlzJbY5kemWjc3XzJJRp\SCjY4Tpeol1gSCxZjDjZZNx[XOnczygZ4F{eGG|ZTC4JIFv\CB7 NIiwO2YzOjh|N{[4PS=>
K562/Adr  NWTDbnRmTnWwY4Tpc44hSXO|YYm= NXnpXoRMPjBizszN M37Ed|EzKGh? NVvHfVRRcW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G|cHHz[UA5KGGwZDC5 Mm[3NlI5Ozd4OEm=
L929sA NUPu[HhESXCxcITvd4l{KEG|c3H5 M{fPS|ExKM7:TR?= MUKxJIg> M1v2[4lvcGmkaYTzJJRp\SCjcH;weI91cWNicnXzdI9ve2VidH:gWG5H Mn\ZNlI{PjJ5Nke=
L929sA NGLoXXhCeG:ydH;zbZMhSXO|YYm= MnPXNVAh|ryP NIfSPG8yKGh? MoW5doV{[3WnczDj[YxteyCneIDy[ZN{cW6pIGLJVGsy|pSLRDDmdo9uKFSQRj3pcoR2[2WmIHHwc5B1d3Orcx?= NWPNeVAyOjJ|NkK3Olc>
L929sA MlvZRZBweHSxc3nzJGF{e2G7 MXqxNEDPxE1? Ml3KNUBp MUjhZpJw\2G2ZYOgeIhmKGmwdHXyZYN1cW:wIH;mJINie3Cjc3WtPEB4cXSqIF\BSGQ> M2jpXVIzOzZ{N{[3
TPC-1 NYfEOpk6S2WubDDWbYFjcWyrdImgRZN{[Xl? NWPvepJbOTByIN88US=> Mo\1NlQhcA>? M2LCeWROW09? NYDzc5pPcW6lcnXhd4V{KGOnbHz1cIFzKHO3co\peoFt NVSwRXBjOjJzM{[4NVg>
8505c Mm\ZR4VtdCCYaXHibYxqfHliQYPzZZk> M3PaXlExOCEQvF2= NVX1WoNOOjRiaB?= MWTEUXNQ NH\qVYZqdmO{ZXHz[ZMh[2WubIXsZZIhe3W{dnn2ZYw> NFfuVJUzOjF|NkixPC=>
SW13 NX7PSYNoS2WubDDWbYFjcWyrdImgRZN{[Xl? M1O1SFExOCEQvF2= M{P2ZlI1KGh? NI\MdoxFVVOR MYXpcoNz\WG|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy= MkfxNlIyOzZ6MUi=
Jurkat  M{i4b2N6fG:2b4jpZ4l1gSCDc4PhfS=> MW[1NE8hOTByL{KwNOKh|ryv NY[0fYlVOS9|IHi= NGns[2dz\WS3Y3XzxsBP[WWpbHXybYEh\m:5bHXybU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? M1XjNVIyPTN3MEKw
Jurkat  M3y4fmZ2dmO2aX;uJGF{e2G7 M4m1elIxOMLizszt NWO5[|ZuOzBibXnu NVzvOXdRemWmdXPld:KhVmGnZ3zldoliKG[xd3zldokucW6mdXPl[EBz\WGldHn2[UBwgHmpZX6gd5Bm[2mnczCoVm9UMSCpZX7ldoF1cW:w MlS5NlE2OzVyMkC=
HT-22 NI\KXoNEgXSxdH;4bYNqfHliQYPzZZk> NUPYSFM4OTBizszN NHOzNWIyOiCq M{WwS5Bzd3SnY4TzJIFo[Wmwc4SgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KDYEoH3tc4wwVCCpbIX0ZY1ifGYEoB?= M2DORlE4PzZyOE[5

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Immunofluorescence
RIP1 / RIP3 ; 

PubMed: 30462730     


Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.

30462730

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

- 合併

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-32P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.
細胞試験:

[2]

- 合併
  • 細胞株: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
  • 濃度: 0.01-100 μM
  • 反応時間: --
  • 実験の流れ:

    Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC6 for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.


    (参考用のみ)

溶解度 (25°C)

体外 DMSO 51 mg/mL (196.66 mM) warming
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+45% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 259.33
化学式

C13H13N3OS

CAS No. 4311-88-0
Storage powder
in solvent
別名 N/A
Smiles CN1C(=O)C(CC2=C[NH]C3=CC=CC=C23)NC1=S

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

TNF-alphaシグナル伝達経路

相関TNF-alpha製品

Tags: Necrostatin-1を買う | Necrostatin-1 ic50 | Necrostatin-1供給者 | Necrostatin-1を購入する | Necrostatin-1費用 | Necrostatin-1生産者 | オーダーNecrostatin-1 | Necrostatin-1化学構造 | Necrostatin-1分子量 | Necrostatin-1代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID